Most people diagnosed with multiple sclerosis live into their 70s. A large 60-year population study from Western Norway found that the median life expectancy for people with MS was 74.7 years, compared to 81.8 years in the general population, a difference of about 7 years. That gap is real, but it’s far smaller than many people fear when they first hear the diagnosis.
How long you live with MS depends heavily on how the disease behaves in your body, how early you start treatment, and how you manage your overall health. The numbers below offer a clearer picture of what shapes that timeline.
Median Survival After Diagnosis
For people newly diagnosed with MS who don’t yet have severe disability, the median survival time is roughly 30 to 35 years from diagnosis. Since most people are diagnosed between their 20s and 40s, that puts the typical age at death somewhere in the late 60s to mid-70s. Finnish registry data tracking deaths through 2020 found that the median age at death for people with MS rose from 52 years before 1980 to 69 years in the 2010 to 2020 period. That steady climb reflects decades of improvement in treatment and care.
These are population-level medians, meaning half of people with MS live longer than these numbers. Many live well into their 80s, especially with milder disease courses.
How Disease Type Affects the Timeline
MS comes in different forms, and the type you have matters more for prognosis than almost any other single factor.
About 85% of people start with relapsing-remitting MS (RRMS), where symptoms flare up and then improve. Many people with RRMS maintain mild disability for years. In one 10-year study of nearly 800 patients, about 74% still had mild disability a decade after disease onset. However, roughly 18% of those patients transitioned to secondary progressive MS (SPMS) during that period, where disability accumulates steadily without clear relapses. That transition is the strongest predictor of severe disability, and people who converted did so after an average of about 5 to 10 years depending on disease severity.
Primary progressive MS (PPMS), which affects about 10 to 15% of people, involves steady worsening from the start without distinct relapses. It typically begins later in life and progresses faster toward mobility loss.
Disability Level and Life Expectancy
Doctors track MS disability on a scale from 0 (no symptoms) to 10. The point on that scale where mortality risk climbs most sharply is when someone loses the ability to walk independently, which corresponds to a score of 6 to 6.5. At that stage, reached at an average age of about 51, people can expect roughly 13 additional years of life. At the most severe end of the scale, where someone is essentially bed-bound (score 9 to 9.5, average age around 71), life expectancy drops to about 1 additional year.
This is why slowing progression matters so much. Every year you delay significant disability is a year added not just to quality of life but, statistically, to lifespan itself.
What People With MS Actually Die From
MS itself rarely causes death directly. Instead, the complications of advanced disability are what shorten life. Respiratory infections are the biggest concern, contributing to nearly 23% of MS-attributed deaths. When mobility declines severely, the risk of aspiration pneumonia (food or liquid entering the lungs) rises sharply, accounting for over 10% of MS-related deaths. Urinary tract infections, a chronic problem for many people with MS due to bladder dysfunction, contributed to about 8% of deaths attributed to the disease.
People with MS also face the same health threats as everyone else. Cardiovascular disease, diabetes, and chronic lung disease all increase the risk of earlier death in MS, just as they do in the general population. Managing these conditions aggressively is one of the most practical things you can do to protect your lifespan.
How Treatment Has Changed the Picture
Disease-modifying therapies (DMTs) have reshaped MS survival. In one Finnish cohort tracked over five decades, DMT use jumped from about 10% to 65% of patients, and those who used DMTs had significantly better survival. A Canadian study found that exposure to any DMT was associated with a 26% lower mortality risk. Norwegian registry data showed that after DMTs became widely available, mortality in people with MS was more than halved.
That said, population-level life expectancy gaps between people with MS and the general population haven’t fully closed yet. The general population’s life expectancy has also been rising, so MS survival is improving alongside broader gains. The clearest takeaway is that starting treatment early and staying on it consistently is associated with living longer.
Race, Ethnicity, and Unequal Outcomes
MS mortality is not evenly distributed across racial groups. In the United States between 1999 and 2015, white and Black Americans had the highest MS mortality rates, while Asian and Pacific Islander Americans had the lowest. A particularly concerning finding: Black Americans with MS had the highest death rates under age 55, and their mortality trends were increasing more steeply than those of white Americans over the study period. This suggests that Black Americans with MS may face faster progression, later diagnosis, or less access to effective treatment.
Lifestyle Factors That Influence Longevity
Beyond medication, several lifestyle choices have strong evidence behind them for slowing MS progression and improving long-term outcomes.
- Quitting smoking is the single most impactful change. Smokers with MS show faster brain shrinkage, more lesions on MRI, and quicker transition to progressive disease. Cessation measurably slows disability worsening.
- Regular physical activity improves fatigue, mobility, and quality of life, and may reduce relapse rates. Both aerobic exercise and strength training have shown benefits in clinical trials.
- Maintaining a healthy weight matters because obesity drives inflammation. Adolescent obesity is linked to higher MS risk in the first place, and excess weight worsens the inflammatory environment throughout the disease.
- Diet quality plays a role as well. Mediterranean-style eating patterns are associated with lower disability levels and reduced symptom burden, while Western-style diets high in processed foods correlate with worse inflammatory and metabolic profiles.
- Sleep has strong biological plausibility as a factor in MS outcomes. The brain’s waste-clearance system is most active during sleep, and poor sleep is linked to higher symptom burden.
None of these replace medication, but they create a more favorable biological environment for treatment to work. Combined with early, consistent DMT use, these factors give people with MS the best statistical chance at a long life.